News & Updates

BIOPHYTIS Gives Updates on its Phase 2-3 COVA Study on COVID-19

03/25/2021

Excerpt from the Press Release: PARIS and CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) — BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“BIOPHYTIS” or the “company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients…

Read More

AI-Fueled COVID-19 Detection Algorithm Slices Report Time 30 Percent

03/24/2021

Excerpt from the Article: A radiology workflow artificial intelligence (AI) solution from RADLogics can help providers truncate their turn-around time for COVID-19 detection cases by up to 30 percent, according to a recently released study. According to a clinical trial conducted at the Moscow Center for Diagnostics & Telemedicine, employing this AI solution to evaluate…

Read More

Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate

03/24/2021

Excerpt from the Press Release: SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that the first patient has been treated in its Phase 1b Amyloid Light Chain (AL) Amyloidosis study of STI-6129, an ADC which uses STI-5171, a fully human monoclonal antibody (mAb) from Sorrento’s G-MAB™ library.…

Read More

BOA™ Biomedical’s GARNET™ therapeutic product begins First in Human clinical trial

03/23/2021

Excerpt from the Press Release: CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ –BOA Biomedical, a Miraki™ Innovation company, focused on rapidly diagnosing and treating some of the world’s deadliest infectious diseases has announced that the company will begin its First in Human clinical trial for GARNET. GARNET is an extracorporeal blood cleansing therapeutic capable of removing…

Read More

Ultrasound May Damage Coronavirus Structure

03/22/2021

Excerpt from the Article: Ultrasound could be a disruptive tool in the fight against COVID-19, according to new research. A recent study published in the Journal of the Mechanics and Physics of Solids has found that the structure of the coronavirus may be vulnerable to the vibrations of an ultrasound with frequencies commonly used in…

Read More

Persephone Biosciences Initiates VOICES Study of Gut Microbiome’s Correlation to Immune Response in COVID-19 Vaccination

03/19/2021

Excerpt from the Press Release: SAN DIEGO, March 11, 2021 /PRNewswire/ — Persephone Biosciences Inc., a privately held, data-driven microbiome-focused biotechnology company, today announced the initiation of the VOICES clinical study to determine the impact of gut microbiome composition and function on the immune system and efficacy of COVID-19 vaccination. VOICES (Vaccine Observation to Include all…

Read More

Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate

03/19/2021

Excerpt from the Press Release: PARIS and LEXINGTON, Mass., March 12, 2021 (GLOBE NEWSWIRE) — Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the…

Read More

aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications

03/18/2021

Excerpt from the Press Release: SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced biomarker results from its Phase 2 double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized…

Read More

First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna’s Next Generation COVID-19 Vaccine

03/17/2021

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participants have been dosed in the Phase 1 study of mRNA-1283, the Company’s next generation COVID-19 vaccine candidate. “We are pleased to begin this Phase 1 study of our…

Read More

Join us at the Clinical Trials Ontario “Clinical Trials During the COVID-19 Pandemic and Beyond” Virtual Conference, March 23rd, 24th, and 25th!

03/16/2021

Clinical Trials Ontario is hosting their annual conference titled “Clinical Trials During the COVID-19 Pandemic and Beyond” and the TrialStat team are exhibiting! “The CTO Conference is a leading Canadian forum to drive innovation in clinical trials, including leaders from the pharmaceutical and medical device industries, academic and healthcare leaders, representatives from patient groups, health…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives